Oral erythromycin and the risk of sudden death from cardiac causes by Ray Wayne A, Murray Katherine T, Meredith Sarah, Narasimhulu Sukumar Suguna, Hall Kathi, Stein C Michael in The New England journal of medicine (2004). PubMed

Abstract

Oral erythromycin prolongs cardiac repolarization and is associated with case reports of torsades de pointes. Because erythromycin is extensively metabolized by cytochrome P-450 3A (CYP3A) isozymes, commonly used medications that inhibit the effects of CYP3A may increase plasma erythromycin concentrations, thereby increasing the risk of ventricular arrhythmias and sudden death. We studied the association between the use of erythromycin and the risk of sudden death from cardiac causes and whether this risk was increased with the concurrent use of strong inhibitors of CYP3A.

[ hide abstract ]

Discussed In Paper